Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come

Executive Summary

Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.

You may also be interested in...



Ease The Pain – Making Payment Models, Tech, Integration Work For Patients

Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference

Medicare Price Inflation Rebates Levied On 27 Part B Drugs In First Round; Pfizer Tops The List

Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.

Medicaid Coverage For PrEP Without Restrictions, Cost Sharing Backed By President’s Budget

Legislation could facilitate faster access without cost sharing or restrictions for new HIV pre-exposure prophylaxis. The White House said its budget proposal to expand Medicare price negotiation would save $160bn more than the Inflation Reduction Act's existing negotiation provisions.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel